NewAmsterdam Pharma Files 8-K on July 30, 2025
Ticker: NAMSW · Form: 8-K · Filed: Jul 30, 2025 · CIK: 1936258
Sentiment: neutral
Topics: corporate-disclosure, filing
Related Tickers: NAMS
TL;DR
NAMS filed an 8-K on 7/30/25 covering stock and warrants.
AI Summary
NewAmsterdam Pharma Co N.V. filed an 8-K on July 30, 2025, reporting on various events. The filing includes information related to common stock and warrants, with a fiscal year end of December 31. The company is incorporated in The Netherlands and its principal executive offices are located in Naarden.
Why It Matters
This 8-K filing provides an update on NewAmsterdam Pharma's corporate structure and financial instruments, which is important for investors tracking the company's status.
Risk Assessment
Risk Level: low — The filing is a routine corporate disclosure and does not appear to contain significant negative or positive news.
Key Players & Entities
- NewAmsterdam Pharma Co N.V. (company) — Registrant
- July 30, 2025 (date) — Date of Report
- The Netherlands (location) — State of Incorporation
- Naarden (location) — City of Principal Executive Offices
FAQ
What is the exact name of the company filing this report?
The exact name of the Registrant is NewAmsterdam Pharma Company N.V.
On what date was this 8-K report filed?
The report was filed on July 30, 2025.
Where is NewAmsterdam Pharma Co N.V. incorporated?
The company is incorporated in The Netherlands.
What is the address of the company's principal executive offices?
The address is Goomieer 2-35, Naarden, The Netherlands, 1411 DC.
What is the company's fiscal year end?
The company's fiscal year ends on December 31.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 30, 2025 regarding NewAmsterdam Pharma Co N.V. (NAMSW).